This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their Research Letter about industry sponsorship of grand rounds, Dr Dieperink and Ms Drogemuller¹ suggest "that the increase in quetiapine fumarate prescriptions was influenced" by a grand rounds sponsored by the manufacturer. However, they do not prove that this increase was due to the meeting or its sponsorship.

While the authors list several caveats to their study, they do not discuss 3 additional methodological questions. First, was the increase in the prescribing of the sponsor's drug significantly greater for prescribers who attended the meeting vs those who did not? The authors could have determined this as they "had data about prescribing behavior at the individual level." Second, was any prescribing increase noted for drugs featured in the 51 nonsponsored meetings vs those not featured at their institution? Third, was there a significant difference in the prescribing increase for drugs featured in the 20 industry-sponsored meetings vs . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Industry-Sponsored Grand Rounds and Prescribing Behavior
Michael E. Dieperink and Lisa Drogemuller
JAMA. 2001;285(11):1443-1444.
EXTRACT | FULL TEXT